Search
A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.
The Gerstner Sloan Kettering Graduate School of Biomedical Sciences welcomed its ninth class of PhD students on July 21, 2014.
Scott N. Keeney, a member of the Molecular Biology Program within the Sloan Kettering Institute, was one of 56 researchers to be appointed a Howard Hughes Medical Institute (HHMI) investigator in 2008.
Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn - which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
Scientists are using a molecule from the immune system to combat this serious complication in a new way.
Mammography has shortcomings but the price is reasonable; MRI is more effective but expensive. Two new modalities — contrast-enhanced digital mammography (CEDM) and abbreviated breast MRI (AB-MRI) — may provide the best of both.
MSK’s Integrative Medicine Service focuses on empowering patients with practices — from acupuncture to music therapy — that fit seamlessly into your care plan.
According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the NMDP registry.
In a recent interview, MSK's Dr. Jeffrey Drebin addressed why it’s important for people to keep up with their routine screenings and not put off cancer treatment or surgery.